EU rejection based on risk of serious brain swelling Lilly seeks re-examination of EU decision on Kisunla CHMP previously rejected Leqembi before recommending approval March 28 (Reuters) - The EU ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease med Kisunla (donanemab) also got a rejection from EU regulators.

INDIANAPOLIS — A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines ...

(Bloomberg) -- Eli Lilly & Co.’s Alzheimer’s disease drug Kisunla failed to get the backing of European regulators, who said its benefits don’t outweigh the risk of potentially fatal ...

A European health committee has rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, because of safety concerns about possible brain swelling and bleeding. Although the drug is already ...

Both Kisunla and Leqembi are laboratory-made antibodies, administered by IV, that target one contributor to Alzheimer’s — sticky amyloid plaque buildup in the brain.

A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines Agency ...